Hannay Michael Charles Ferguson 4

What Happened

• Michael Charles Ferguson Hannay, Bicycle Therapeutics' Chief Product & Supply Chain Officer, was granted a derivative award on 2026-07-15 to acquire 60,000 shares. The Form 4 records the acquisition price as $0.00 (typical for option grants); the filing lists the transaction as an award/grant (code A) rather than an open-market purchase or sale. No immediate sale occurred.

Key Details

• Transaction date: 2026-07-15; Form 4 filed: 2026-07-17 (timely within the usual 2-business-day window).
• Award: right/option to acquire 60,000 shares; reported acquisition price $0.00 (derivative security).
• Shares owned after the transaction: not disclosed in the provided filing details.
• Footnote: the option vests 1/4 on July 15, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter (standard multi-year vesting).
• Filing type/code: A = award/grant of derivative securities.

Context

• This is a compensation-related option grant that vests over time; it does not represent an immediate purchase or sale of stock. Such awards are common for executives and are intended to align incentives over multiple years. Because it’s a grant (not a purchase), it should be viewed as routine compensation rather than a direct signal of short-term buying or selling intent.